These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33906942)

  • 1. Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice.
    Aryal S; Longo F; Klann E
    Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33906942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
    Bhattacharya A; Kaphzan H; Alvarez-Dieppa AC; Murphy JP; Pierre P; Klann E
    Neuron; 2012 Oct; 76(2):325-37. PubMed ID: 23083736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade.
    Narayanan U; Nalavadi V; Nakamoto M; Thomas G; Ceman S; Bassell GJ; Warren ST
    J Biol Chem; 2008 Jul; 283(27):18478-82. PubMed ID: 18474609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome.
    Kalinowska M; van der Lei MB; Kitiashvili M; Mamcarz M; Oliveira MM; Longo F; Klann E
    Mol Autism; 2022 Jun; 13(1):29. PubMed ID: 35768828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice.
    Bhattacharya A; Mamcarz M; Mullins C; Choudhury A; Boyle RG; Smith DG; Walker DW; Klann E
    Neuropsychopharmacology; 2016 Jul; 41(8):1991-2000. PubMed ID: 26708105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.
    Kumari D; Bhattacharya A; Nadel J; Moulton K; Zeak NM; Glicksman A; Dobkin C; Brick DJ; Schwartz PH; Smith CB; Klann E; Usdin K
    Hum Mutat; 2014 Dec; 35(12):1485-94. PubMed ID: 25224527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
    Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
    Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragile X Mental Retardation Protein (FMRP) controls diacylglycerol kinase activity in neurons.
    Tabet R; Moutin E; Becker JA; Heintz D; Fouillen L; Flatter E; Krężel W; Alunni V; Koebel P; Dembélé D; Tassone F; Bardoni B; Mandel JL; Vitale N; Muller D; Le Merrer J; Moine H
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3619-28. PubMed ID: 27233938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The translation of translational control by FMRP: therapeutic targets for FXS.
    Darnell JC; Klann E
    Nat Neurosci; 2013 Nov; 16(11):1530-6. PubMed ID: 23584741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
    Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
    J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
    Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
    Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
    De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
    Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.
    Hoeffer CA; Sanchez E; Hagerman RJ; Mu Y; Nguyen DV; Wong H; Whelan AM; Zukin RS; Klann E; Tassone F
    Genes Brain Behav; 2012 Apr; 11(3):332-41. PubMed ID: 22268788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
    Gross C; Nakamoto M; Yao X; Chan CB; Yim SY; Ye K; Warren ST; Bassell GJ
    J Neurosci; 2010 Aug; 30(32):10624-38. PubMed ID: 20702695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.
    Iliff AJ; Renoux AJ; Krans A; Usdin K; Sutton MA; Todd PK
    Hum Mol Genet; 2013 Mar; 22(6):1180-92. PubMed ID: 23250915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of GpI mGluR-Dependent Cav2.3 Translation in a Mouse Model of Fragile X Syndrome.
    Gray EE; Murphy JG; Liu Y; Trang I; Tabor GT; Lin L; Hoffman DA
    J Neurosci; 2019 Sep; 39(38):7453-7464. PubMed ID: 31350260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant RNA translation in fragile X syndrome: From FMRP mechanisms to emerging therapeutic strategies.
    Banerjee A; Ifrim MF; Valdez AN; Raj N; Bassell GJ
    Brain Res; 2018 Aug; 1693(Pt A):24-36. PubMed ID: 29653083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.
    Sawicka K; Pyronneau A; Chao M; Bennett MV; Zukin RS
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6290-E6297. PubMed ID: 27663742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNAs and Fragile X Syndrome.
    Lin SL
    Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase pathway inhibition restores PSD95 induction in neurons lacking fragile X mental retardation protein.
    Yang Y; Geng Y; Jiang D; Ning L; Kim HJ; Jeon NL; Lau A; Chen L; Lin MZ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):12007-12012. PubMed ID: 31118285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.